October 31, 2013 - AML: Update on Diagnosis and Treatment
- Signs or symptoms of acute myeloid leukemia (AML)
- Blood and marrow tests used to diagnose AML
- Current and emerging treatment options
- Treatment side effects and strategies for side effect management
- The role of clinical trials in the continuing improvement of AML treatment outcomes
Elihu H. Estey, MD
Professor, Division of Hematology
University of Washington School of Medicine
Member and Director of AML Clinical Research (non transplant)
Clinical Research Division
Fred Hutchinson Cancer Research Center
Questions Asked by the AML Community
- What is the next step for a patient whose blood counts do not recover after consolidation therapy and cannot receive additional chemotherapy?
- What are signs of rejection after a transplant?
- Is the treatment for pediatric acute myeloid leukemia (AML) the same as for adults?
- What does it mean to say that azacitidine (Vidaza®) is a statistically better treatment?
- Are there options for patients who relapse after an allogeneic stem cell transplant?
- Does graft-versus-host disease ever stop?
- Could you speak to fertility concerns with young patients who will undergo stem cell transplantation?
- Why didn't you mention autologous stem cell transplantation?
- Is there a difference in outcome for patients who need two inductions rather than one to achieve remission?
- What testing needs to be done to know if a patient's sister's umbilical cord blood would be a match?
- What is acute promyelocytic leukemia (APL) and what is the current standard of care?
- What does it mean to have a high white blood count and why does it need to be treated so quickly?
- Do high white blood cell counts at diagnosis make a difference to a patient's prognosis?
- Why don't we do more autologous transplants to help and perhaps eliminate graft-versus-host disease?
- How common is it to develop multiple health problems more than three years after transplantation?
Sponsors and Supporters
This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Sunesis Pharmaceuticals.